Prostate Cancer Canada

PSA

PSA Controversy

For more information visit
www.movember.com

In The News

PSA Fitness (Power, Strength & Agility)
HALIFAX, N.S., January 16, 2012/CNW/ Prostate Cancer Canada Atlantic is proud to announce the launch of PSA Fitness (Power, Strength & Agility), a free nine week exercise program for men who have been diagnosed with prostate cancer. PSA Fitness, resistance training and yoga, is an important patient-centered therapy for prostate cancer survivors in Halifax.

TELUS donation to support Prostate Cancer Canada
Toronto, ON- January 13, 2012- On January 10th, Prostate Cancer Canada received a generous donation of $100,000 from TELUS at the launch of the TIEd Together exhibition. TELUS’ donation was made possible through the Canadian Football League Grey Cup cause marketing campaign. The donation will support Prostate Cancer Canada’s ongoing efforts to eliminate the disease through research, education, support and awareness.

Click For Information Archive

Prostate Cancer Canada is a strong supporter of PSA testing as one form of early detection. However, like most cancer diagnostic tools, the PSA blood test is, in certain circles, controversial. Please see below for a information regarding the pros and cons of PSA testing.

The The U.S. Preventive Services Task Force is not for or against routine PSA or DRE testing because of lack of evidence.

The National Cancer Institute (U.S.) believes there are no standard or routine tests to screen for prostate cancer.

The The American Cancer Society does not recommend routine testing, but believes that doctors should offer the PSA and DRE to their patients yearly starting at age 50, and discuss with them the benefits and limitations of testing.

The The American Urological Association believes that men should be informed of the known risks and potential benefits of PSA testing and that this discussion should start at age 40.

The World Health Organization says that it is not clear if screening for prostate cancer with the PSA test reduces the number of deaths from the disease.

The United Kingdom National Health Service says that evidence does not yet support screening for prostate cancer.